Amoytop Biotech

Executive Summary

Amoytop Biotech is a Chinese biopharmaceutical company focused on the development and commercialization of recombinant protein drugs, with a core expertise in PEGylation technology to create long-acting cytokine therapies. The company targets chronic hepatitis B (CHB), oncology, and immunotherapy indications, leveraging its proprietary platform to improve drug half-life and patient compliance. Founded in 2003 and publicly listed, Amoytop has established itself as a commercial-stage player with a portfolio of marketed products and a robust pipeline of next-generation biologics. Amoytop's strategic focus on CHB aligns with a significant unmet medical need in China and globally, where current treatments offer limited cure rates. Its oncology and immunotherapy programs further diversify its pipeline, targeting key growth areas in immuno-oncology. The company's PEGylation platform provides a competitive edge in developing long-acting biologics with enhanced efficacy and safety profiles. With a commercial presence and multiple late-stage clinical assets, Amoytop is well-positioned to capture market share in the rapidly growing Chinese biopharma sector and potentially expand internationally through partnerships.

Upcoming Catalysts (preview)

• H2 2026NMPA approval decision for long-acting PEGylated interferon for CHB75% success
• Q1 2026Phase 3 top-line data for anti-PD-1 long-acting fusion protein in solid tumors60% success
• TBDLicensing deal with global pharma for PEGylation technology platform40% success